WILLOW LABORATORIES for WILLOW LABORATORIES
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
No amount is shown when the filer reports less than $5,000 for the period, which the form does not ask them to state.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Dec 15, 2025 | — | Replaced |
| 4th Quarter - Amendment | Mar 5, 2026 | — | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Support for coverage and reimbursement for diabetes prevention and wellness technologies; patient safety; support for PBM reform and corporate governance.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE MEIER | — |
Medicare/Medicaid MMM
Support for increased Medicare and Medicaid coverage and reimbursement for diabetes prevention technologies
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE MEIER | — |
Financial Institutions/Investments/Securities FIN
corporate governance and transparency
| Lobbyist | Covered position, as disclosed |
|---|---|
| CATHERINE MEIER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.